[Current management of atrial fibrillation: rhythm or rate control and thoughts about a new treatment paradigm]
Related Experiment Video
Updated: Jun 5, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
1CHRU de Lille - Hôpital Cardiologique, France. salem.kacet@chru-lille.fr
Insights
Atrial fibrillation treatment has evolved over 30 years, shifting from rhythm control to preventing stroke and improving quality of life. New therapies like ablation and anticoagulants offer improved atrial fibrillation management.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Context:
- Treatment for atrial fibrillation (AF) has undergone significant evolution over the last three decades.
- Historically, the focus was on restoring sinus rhythm, but shifted towards thrombo-embolic event prevention and rate versus rhythm control.
- Current objectives in AF management include symptom reduction, quality of life improvement, and mortality decrease.
Purpose:
- To review the historical changes in atrial fibrillation treatment paradigms.
- To highlight the evolution of therapeutic goals and strategies in managing atrial fibrillation patients.
- To discuss the impact of clinical trials and emerging therapies on AF management.
Summary:
- The CAST trial (pre-1989) shifted focus from rhythm control to thrombo-embolic prevention.
- The past 20 years emphasized anticoagulation and the rate versus rhythm control debate.
- Current goals (post-2010) include symptom relief, quality of life, and mortality reduction, with new anticoagulants and ablation techniques.
Impact:
- Ablative techniques are now standard for selected younger patients with refractory AF.
- Rate control is suitable for permanent AF or as a second-line option.
- New anticoagulants and antiarrhythmics like dronedarone (ATHENA trial) represent advancements in AF care.
Abstract:
Over the past 30 years, treatment paradigms for atrial fibrillation (AF) patients have changed dramatically. Before 1989, and the publication of the CAST trial results, the primary objective was to maintain or restore sinus rhythm. In the following 20 years, the management of AF patients has focused on the prevention of thrombo-embolic events (with the confrontation of aspirin and oral anticoagulants), and on the debate between rhythm control and rate control. In 2010, the objectives are to reduce symptoms and improve quality of life, to prevent thrombo-embolic complications, and, if possible, to reduce mortality. New anticoagulants will soon be available. Ablative techniques are becoming current practice in selected patients, and the new antiarrhythmic agent dronedarone has shown remarkable clinical results in the ATHENA trial. Overall, ablative techniques can be used in younger patients with paroxysmal or persistent AF refractory to medical treatment a rate control strategy is appropriate in permanent AF, or as second line treatment in patients with other forms of AF.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmias VII: Nursing Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Mitral Regurgitation III: Medical Management
Rheumatic Heart Disease III: Medical Management

